Core Viewpoint - The short drama "Northeast Love Story: Flash Marriage Rose," produced by Xingning Culture under Ningmeng Film and Television, has achieved over 1 billion views, with 300 million views within the first three days of its release, highlighting the project's rapid success in a competitive short drama market [1] Company Summary - Xingning Culture, a short drama brand under Ningmeng Film and Television, has successfully applied the high-quality production principles from long-form content to short dramas, demonstrating a commitment to excellence in script refinement, actor performance, and scene restoration [1] - The production team emphasizes a strong sense of era, detailed character portrayal, and profound emotional expression, proving that short dramas can address serious contemporary issues and convey deep cultural concerns [1] Industry Summary - The short drama market is becoming increasingly competitive, yet the success of "Northeast Love Story: Flash Marriage Rose" indicates that high-quality production and genuine emotional storytelling can lead to significant viewer engagement and popularity [1]

Core Viewpoint - The short drama "Northeast Love Story: Flash Marriage Rose," produced by Xingning Culture, a subsidiary of Ningmeng Film and Television, has achieved over 1 billion views, with 300 million views within the first three days of its release, highlighting the project's rapid success in a competitive short drama market [1] Group 1: Company Overview - Xingning Culture is a short drama brand under Ningmeng Film and Television, inheriting the group's expertise in long-form content production [1] - The production team applies high standards to script refinement, actor performances, and scene restoration, ensuring quality in short drama creation [1] Group 2: Industry Insights - The success of "Northeast Love Story: Flash Marriage Rose" demonstrates that short dramas can effectively address serious contemporary issues and convey profound humanistic concerns [1] - The project exemplifies a "long-termism" approach, successfully breaking through the quality barriers typically associated with short dramas [1]

自願公告 業務發展最新情況 本公告乃經檸萌影視傳媒有限公司（「本公司」或「檸萌影視」，連同其附屬公司及並表聯屬 實體統稱「本集團」）自願作出，旨在向本公司股東及潛在投資者更新本集團之最新業務發 展。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Linmon Media Limited 9857 承董事會命 檸萌影視傳媒有限公司 董事長 蘇曉 中國，北京 2025年10月27日 於本公告日期，本公司執行董事為蘇曉先生、陳菲女士及徐曉鷗女士；本公司非執行董 事為王娟女士及張嶸先生；本公司獨立非執行董事為蔣昌建先生、唐松蓮女士及梁寧女 士。 本公司董事會（「董事會」）欣然宣佈，由檸萌影視旗下短劇廠牌星檸文化製作的短劇《東北 愛情往事：閃婚玫瑰》累計播放量突破10億次大關，上線3天播放量即突破3億次。在當前 競爭日趨激烈的短劇市場，該項目的迅速走紅，來源於精良的製作和真摯的情感表達， 以「長期主義」有效實現短劇品質破圈。 作為該項目的製作方，星檸文化是本 ...

Core Insights - The rapid development of internet technology, diverse audience demands for entertainment content, supportive policies, and the entry of internet giants like Douyin and Kuaishou have led to a significant explosion in China's short drama industry, with a market size projected to reach 50.5 billion yuan in 2024, a year-on-year increase of 35% [1][5][6] - The global AI short drama market has entered a phase of explosive growth since the second half of 2024, with notable advancements in AI video generation models enhancing production efficiency and creativity [1][7][9] AI Short Drama Industry Overview - AI short dramas utilize artificial intelligence to generate visuals, plots, and other elements, significantly reducing production time to "hour-level" and costs to as low as 1% of traditional methods [3][4] - The industry has evolved through four stages: technology emergence (2018-2020), tool exploration (2021-2022), industry explosion (2023-2024), and ecosystem formation (2025 onwards) [3][4] AI Short Drama Industry Policies - The Chinese government has implemented various policies to promote the AI short drama industry, including the 2025 notice encouraging innovation in micro-short drama creation and integration with AI technology [5][6] Current Development of AI Short Drama Industry - The short drama format has gained popularity due to its suitability for fragmented viewing time, with several high-quality productions emerging, such as "Escape from the British Museum" and "My Return Journey Has Wind" [1][5] - The market size for short dramas in China is expected to reach 50.5 billion yuan in 2024, reflecting a 35% increase from the previous year [1][6] AI Short Drama Industry Competition Landscape - The competition in the AI short drama industry involves technology vendors (e.g., Baidu, Tencent), content producers (traditional and new teams), and platform operators (Douyin, Kuaishou, Bilibili) [9][10] AI Short Drama Industry Development Trends - Continuous technological innovation will drive the expansion of AI short dramas, with advancements in real-time animation and emotional algorithms enhancing artistic expression [13][14] - "Human-machine collaboration" will be crucial for improving the quality of AI short dramas, allowing creators to focus on core storytelling while AI handles complex visual elements [14][15] - Interactivity and personalization will distinguish AI short dramas from traditional media, enabling viewers to influence storylines and customize characters, thus enhancing engagement [15]

Core Viewpoint - The announcement highlights the commencement of filming for the drama "Small Town Prescription," produced by Lingmeng Film and co-produced by iQIYI, indicating a strategic collaboration in the entertainment industry [1] Group 1: Production Details - The drama "Small Town Prescription" began filming on October 18, 2025 [1] - The script is written by Nie Chengshuai, directed by Zhang Xiaobo, with Su Xiao as the executive producer and Xia Jie as the producer [1] Group 2: Cast Information - The lead role is played by the prominent young actor Xiao Zhan, supported by a strong cast including Ni Dahong, Jiang Yan, Shi Pengyuan, Kan Renzi, and Zhang Guoqiang [1]

Core Viewpoint - The article announces that Ningmeng Film and Television (09857.HK) has commenced filming for the healing drama "Small Town Prescription," co-produced with iQIYI, starting on October 18, 2025 [1] Group 1 - The drama "Small Town Prescription" is produced by Ningmeng Film and Television and co-produced by iQIYI [1] - The script is written by Nie Chengshuai, directed by Zhang Xiaobo, with Su Xiao as the executive producer and Xia Jie as the producer [1] - The lead role is played by popular young actor Xiao Zhan, alongside notable actors Ni Dahong, Jiang Yan, Shi Pengyuan, Guan Renzi, and Zhang Guoqiang [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Linmon Media Limited 承董事會命 檸萌影視傳媒有限公司 9857 自願公告 業務發展最新情況 本公告乃經檸萌影視傳媒有限公司（「本公司」或「檸萌影視」，連同其附屬公司及併表聯屬 實體統稱「本集團」）自願作出，旨在向本公司股東及潛在投資者更新本集團之最新業務發 展。 本公司董事會（「董事會」）欣然宣佈，由檸萌影視出品，愛奇藝聯合出品的小城生活「療」 愈劇《小城良方》，已於2025年10月18日開機拍攝。該劇由聶成帥編劇，張曉波導演，蘇 曉擔任總製片人，夏傑擔任製片人，實力青年演員肖戰領銜主演，倪大紅、姜妍、史彭 元、菅紉姿、張國強領銜主演。 董事長 蘇曉 中國，北京 2025年10月20日 於本公告日期，本公司執行董事為蘇曉先生、陳菲女士及徐曉鷗女士；本公司非執行董 事為王娟女士及張嶸先生；本公司獨立非執行董事為蔣昌建先生、唐松蓮女士及梁寧女 士。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 檸萌影視傳媒有限公司 呈交日期: 2025年10月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09857 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/註冊股 ...

Major Events - Lai Kai Pharmaceutical-B (02105) reported positive preliminary results from Phase I clinical MAD study, with LAE102 showing encouraging trends in muscle gain and fat loss [1] - Fuhong Hanlin (02696) received FDA approval for the Phase I clinical trial application of HLX13 for first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] - Ningmeng Media (09857) has commenced filming the urban medical emotional drama "Asking Heart 2" [1] - CRRC Corporation (01766) and its subsidiaries signed significant contracts totaling approximately 54.34 billion [1] - Heng Rui Pharmaceutical (01276) received approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] - Hema Medical (03309) entered into a tripartite global licensing and collaboration agreement with Gilead and Hanmi regarding enecuidar [1] - Jinfang Pharmaceutical-B (02595) completed the enrollment of the first patient in the Phase I/II clinical trial of the molecular glue Pan RAS(ON) inhibitor GFH276 for RAS mutant cancer patients [1] - Gao Shi Medical (02407) obtained international certification for its medical device quality management system [1] Operating Performance - Shenzhen Expressway Company (00548) reported toll revenue of 114 million for the Outer Ring project in August [1] - China National Automobile (00026) announced an annual performance with a post-tax loss attributable to shareholders of 185 million HKD, a year-on-year reduction of 29.64% [1] - OKURA HOLDINGS (01655) reported an annual profit attributable to shareholders of 1.342 billion JPY, a year-on-year decrease of 34.34% [1] - Elephant Future Group (02309) disclosed an annual performance with a loss attributable to owners of approximately 314 million HKD, a year-on-year increase of 71.77% [1] - Henghe Group (00513) reported an annual performance with a loss attributable to owners of approximately 259 million HKD, a year-on-year increase of 0.7% [1]

智通财经APP讯，柠萌影视(09857)发布公告，由国家安全部重点指导，中央广播电视总台、中国电视剧 制作中心、柠萌影视及旗下柠萌开新、腾讯视频出品的当代国安题材电视剧《交锋》，已于2025年9月 29日开机拍摄。该剧由王小枪编剧，姚晓峰总导演，张翼芸担任总制片人，王凯领衔主演，彭昱畅特别 主演，欧豪特邀主演。 ...